Ligand Pharmaceuticals Stock Price, News & Analysis (NASDAQ:LGND)

$155.81 5.25 (3.49 %)
(As of 01/22/2018 03:09 AM ET)
Previous Close$150.56
Today's Range$150.81 - $156.30
52-Week Range$95.08 - $156.30
Volume501,600 shs
Average Volume241,723 shs
Market Capitalization$3.29 billion
P/E Ratio225.81
Dividend YieldN/A
Beta0.91

About Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Debt-to-Equity Ratio0.05%
Current Ratio0.97%
Quick Ratio0.95%

Price-To-Earnings

Trailing P/E Ratio225.811594202899
Forward P/E Ratio49.46
P/E Growth1.67

Sales & Book Value

Annual Sales$108.97 million
Price / Sales30.17
Cash Flow$0.97 per share
Price / Cash161.27
Book Value$16.33 per share
Price / Book9.54

Profitability

Trailing EPS$0.69
Net Income$-1,630,000.00
Net Margins12.76%
Return on Equity7.83%
Return on Assets4.64%

Miscellaneous

Employees22
Outstanding Shares21,100,000

Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its earnings results on Thursday, November, 9th. The biotechnology company reported $0.69 EPS for the quarter, beating the Zacks' consensus estimate of $0.37 by $0.32. The biotechnology company had revenue of $33.38 million for the quarter, compared to analysts' expectations of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The firm's revenue was up 54.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.62 earnings per share. View Ligand Pharmaceuticals' Earnings History.

When will Ligand Pharmaceuticals make its next earnings announcement?

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Ligand Pharmaceuticals.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY17 earnings guidance on Wednesday, January, 3rd. The company provided earnings per share (EPS) guidance of $3.13-3.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.98. The company issued revenue guidance of ~$140 million, compared to the consensus revenue estimate of $135.72 million.

Where is Ligand Pharmaceuticals' stock going? Where will Ligand Pharmaceuticals' stock price be in 2018?

5 analysts have issued 12 month target prices for Ligand Pharmaceuticals' stock. Their forecasts range from $105.00 to $170.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $147.80 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals.

What are Wall Street analysts saying about Ligand Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:

  • 1. HC Wainwright analysts commented, "We View Licensing of Macrilen as Highly Synergistic; Reit Buy and $18 PT Ahead of Recorlev Data in 2Q18 What’s new? Yesterday, Strongbridge announced the acquisition of U.S. and Canadian rights for Macrilen, a newly approved drug for the diagnostic testing of adult growth hormone deficiency (AGHD). In our opinion, this acquisition confirms SBBP’s confidence in the upcoming Recorlev trial and stakes a claim as potentially having two compounds in the rare endocrine space. Moreover, we view targeting the AGHD diagnostic field as a thus far untapped market that we believe will include traumatic brain injury patients with a wide degree of severity. Lastly, we believe that the endocrine community is well versed in the use of pharmacological agents as diagnostics and that uptake and acceptance of this approach should be fairly straight-forward. With this new agent in house as well as top-line data for Recorlev on deck in 2Q18, we reiterate our Buy rating and $18 price target." (1/18/2018)
  • 2. According to Zacks Investment Research, "Ligand is highly dependent on its Captisol-based partners for revenue. If any of the company’s partners fails to receive regulatory approval or terminates a deal, Ligand’s future prospects would be severely hampered. The company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to either of these two products could leave a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtains Captisol is alos concerning. However, the company’s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is encouraging. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Shares of Ligand have outperformed the broader industry in the last one year." (1/2/2018)

Who are some of Ligand Pharmaceuticals' key competitors?

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the folowing people:

  • Matthew W. Foehr, President, Chief Operating Officer (Age 44)
  • John L. Higgins, Chief Executive Officer, Director (Age 47)
  • Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance (Age 42)
  • Charles S. Berkman J.D., Vice President, General Counsel, Secretary (Age 48)
  • John W. Kozarich, Non-Executive Independent Chairman of the Board (Age 67)
  • Nancy Ryan Gray, Director (Age 58)
  • Jason M. Aryeh, Independent Director (Age 48)
  • Todd C. Davis, Independent Director (Age 56)
  • John L. LaMattina Ph.D., Independent Director (Age 67)

Who owns Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.62%), AMI Asset Management Corp (0.58%), Convergence Investment Partners LLC (0.07%), Bank of Montreal Can (0.05%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Melanie J Herman and Stephen L Sabba. View Institutional Ownership Trends for Ligand Pharmaceuticals.

Who sold Ligand Pharmaceuticals stock? Who is selling Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including AMI Asset Management Corp. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew E Korenberg, Matthew W Foehr and Stephen L Sabba. View Insider Buying and Selling for Ligand Pharmaceuticals.

Who bought Ligand Pharmaceuticals stock? Who is buying Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc., Convergence Investment Partners LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Ligand Pharmaceuticals.

How do I buy Ligand Pharmaceuticals stock?

Shares of Ligand Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of Ligand Pharmaceuticals stock can currently be purchased for approximately $155.81.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $3.29 billion and generates $108.97 million in revenue each year. The biotechnology company earns $-1,630,000.00 in net income (profit) each year or $0.69 on an earnings per share basis. Ligand Pharmaceuticals employs 22 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


MarketBeat Community Rating for Ligand Pharmaceuticals (LGND)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ligand Pharmaceuticals (NASDAQ:LGND) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.752.75
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $147.80$146.60$139.00$133.60
Price Target Upside: 1.02% downside12.56% upside3.12% downside14.43% upside

Ligand Pharmaceuticals (NASDAQ:LGND) Consensus Price Target History

Price Target History for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018HC WainwrightReiterated RatingBuy$169.00LowView Rating Details
11/20/2017Deutsche BankDowngradeHold -> Sell$105.00N/AView Rating Details
11/15/2017Craig HallumReiterated RatingBuy$160.00 -> $170.00N/AView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$158.00N/AView Rating Details
8/9/2017StephensReiterated RatingOverweight$125.00 -> $137.00LowView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings History and Estimates Chart

Earnings by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ LGND) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$1.06N/AView Earnings Details
11/9/2017Q3 2017$0.37$0.69$31.04 million$33.38 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.25$0.67$24.40 million$28.00 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
8/8/2012Q2 2012($0.03)($0.20)ViewN/AView Earnings Details
5/2/2012Q1 2012$0.02($0.02)ViewN/AView Earnings Details
2/7/2012Q4 2011$0.02$0.24ViewN/AView Earnings Details
11/8/2011Q3 2011($0.20)ViewN/AView Earnings Details
8/8/2011Q2 2011$0.01($0.05)ViewN/AView Earnings Details
5/10/2011Q1 2011$0.04($0.06)ViewN/AView Earnings Details
2/15/2011Q4 2010$0.02$0.24ViewN/AView Earnings Details
11/9/2010Q3 2010($3.62)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.06($0.01)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.18)($0.15)ViewN/AView Earnings Details
2/9/2010Q4 2009$0.07ViewN/AView Earnings Details
11/5/2009Q3 2009($0.30)($0.18)ViewN/AView Earnings Details
8/3/2009Q2 2009($0.42)($0.22)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.24)($0.29)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.36)($0.11)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.42)($0.31)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.12)($0.61)ViewN/AView Earnings Details
2/20/2008Q4 2007$0.24($0.34)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings Estimates

Current Year EPS Consensus Estimate: $3.15 EPS
Next Year EPS Consensus Estimate: $3.39 EPS

Dividends

Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Insider Trades by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018John W KozarichDirectorSell2,500$145.00$362,500.0033,149View SEC Filing  
12/20/2017Stephen L SabbaDirectorSell925$137.25$126,956.2526,985View SEC Filing  
11/17/2017Matthew E KorenbergVPSell6,559$142.63$935,510.178,147View SEC Filing  
11/16/2017John L HigginsCEOSell5,269$142.53$750,990.57143,542View SEC Filing  
11/16/2017John W KozarichDirectorSell5,000$141.71$708,550.0035,649View SEC Filing  
9/5/2017John L HigginsCEOSell5,000$130.00$650,000.00144,171View SEC Filing  
8/23/2017Jason AryehDirectorSell2,000$127.99$255,980.0059,625View SEC Filing  
8/9/2017Charles S BerkmanVPSell18,625$126.96$2,364,630.0024,423View SEC Filing  
8/9/2017Matthew W FoehrInsiderSell6,100$127.51$777,811.00101,020View SEC Filing  
8/8/2017John L HigginsCEOSell5,483$125.00$685,375.00144,654View SEC Filing  
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00143,837View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00151,171View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.7258,959View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.2098,341View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00139,171View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.8197,599View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.0058,959View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.4958,959View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.4058,959View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00122,664View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.0039,983View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.4040,783View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.0041,783View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.0042,883View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.0043,361View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.003,297View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.0058,337View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.0043,911View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.0044,711View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.0083,062View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.2258,337View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51120,220View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.0449,711View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.003,151View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.0032,536View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.0021,356View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.0063,743View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.8031,243View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.0053,457View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.0044,929View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.0017,667View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.0063,743View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.4226,936View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.2917,928View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00116,581View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.0024,166View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ligand Pharmaceuticals (NASDAQ LGND) News Headlines

Source:
DateHeadline
HC Wainwright Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)HC Wainwright Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)
www.americanbankingnews.com - January 21 at 11:38 PM
Ligand Pharmaceuticals Inc. (LGND) Expected to Announce Quarterly Sales of $46.81 MillionLigand Pharmaceuticals Inc. (LGND) Expected to Announce Quarterly Sales of $46.81 Million
www.americanbankingnews.com - January 19 at 8:40 AM
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic ImagingLigand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging
finance.yahoo.com - January 18 at 4:45 PM
5 Big Biotech Stocks To Buy In 2018 - Investorplace.com5 Big Biotech Stocks To Buy In 2018 - Investorplace.com
investorplace.com - January 18 at 10:32 AM
Ligand Pharmaceuticals Inc. (LGND) Expected to Announce Earnings of $1.06 Per ShareLigand Pharmaceuticals Inc. (LGND) Expected to Announce Earnings of $1.06 Per Share
www.americanbankingnews.com - January 17 at 1:18 PM
Ligand Pharmaceuticals Inc. (LGND) Receives Consensus Rating of "Buy" from AnalystsLigand Pharmaceuticals Inc. (LGND) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 15 at 7:42 AM
HC Wainwright Analysts Give Ligand Pharmaceuticals (LGND) a $169.00 Price TargetHC Wainwright Analysts Give Ligand Pharmaceuticals (LGND) a $169.00 Price Target
www.americanbankingnews.com - January 13 at 11:46 PM
Ligand Pharmaceuticals Inc. (LGND) Director John W. Kozarich Sells 2,500 SharesLigand Pharmaceuticals Inc. (LGND) Director John W. Kozarich Sells 2,500 Shares
www.americanbankingnews.com - January 11 at 6:58 PM
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark PharmaceuticalsLigand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
finance.yahoo.com - January 11 at 9:58 AM
Ligand Pharmaceuticals (LGND) Upgraded to "Strong-Buy" at BidaskClubLigand Pharmaceuticals (LGND) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - January 6 at 12:48 AM
ANI Pharmaceuticals (ANIP) vs. Ligand Pharmaceuticals (LGND) Financial SurveyANI Pharmaceuticals (ANIP) vs. Ligand Pharmaceuticals (LGND) Financial Survey
www.americanbankingnews.com - January 5 at 3:32 AM
Ligand Pharmaceuticals (LGND) Updates FY17 Earnings GuidanceLigand Pharmaceuticals (LGND) Updates FY17 Earnings Guidance
www.americanbankingnews.com - January 3 at 5:28 PM
Ligand Earns $6 Mln As HanAll Out-Licenses Antibody ProjectsLigand Earns $6 Mln As HanAll Out-Licenses Antibody Projects
www.nasdaq.com - January 3 at 5:13 PM
Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody ProjectsLigand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects
finance.yahoo.com - January 3 at 5:13 PM
Ligand Pharmaceuticals (LGND) Downgraded by Zacks Investment ResearchLigand Pharmaceuticals (LGND) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
$44.98 Million in Sales Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter$44.98 Million in Sales Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter
www.americanbankingnews.com - January 2 at 4:26 AM
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : January 1, 2018Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : January 1, 2018
finance.yahoo.com - January 1 at 9:35 AM
$1.06 EPS Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter$1.06 EPS Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter
www.americanbankingnews.com - December 31 at 7:32 PM
[$$] KeyBanc: Tesla Model 3 Deliveries May Disappoint[$$] KeyBanc: Tesla Model 3 Deliveries May Disappoint
finance.yahoo.com - December 31 at 9:27 AM
Ligand Pharmaceuticals (LGND) Given a $169.00 Price Target by HC Wainwright AnalystsLigand Pharmaceuticals (LGND) Given a $169.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 28 at 10:14 PM
ETFs with exposure to Ligand Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Ligand Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 9:02 AM
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:59 PM
Ligand Pharmaceuticals Inc. (LGND) Director Stephen L. Sabba Sells 925 SharesLigand Pharmaceuticals Inc. (LGND) Director Stephen L. Sabba Sells 925 Shares
www.americanbankingnews.com - December 21 at 8:40 AM
Ligand Pharmaceuticals Inc. (LGND) Given Average Recommendation of "Hold" by BrokeragesLigand Pharmaceuticals Inc. (LGND) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 21 at 8:12 AM
Ligand Pharmaceuticals Inc. (LGND) Expected to Post Quarterly Sales of $44.98 MillionLigand Pharmaceuticals Inc. (LGND) Expected to Post Quarterly Sales of $44.98 Million
www.americanbankingnews.com - December 17 at 4:08 PM
 Analysts Anticipate Ligand Pharmaceuticals Inc. (LGND) to Announce $1.06 Earnings Per Share Analysts Anticipate Ligand Pharmaceuticals Inc. (LGND) to Announce $1.06 Earnings Per Share
www.americanbankingnews.com - December 15 at 1:28 AM
5 Top Biotech Stocks to Buy Now5 Top Biotech Stocks to Buy Now
finance.yahoo.com - December 3 at 9:43 AM
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
finance.yahoo.com - November 29 at 5:31 PM
Reviewing Ligand Pharmaceuticals (LGND) & Regulus Therapeutics (RGLS)Reviewing Ligand Pharmaceuticals (LGND) & Regulus Therapeutics (RGLS)
www.americanbankingnews.com - November 29 at 5:30 AM
Ligand Pharmaceuticals (LGND) PT Set at $163.00 by HC WainwrightLigand Pharmaceuticals (LGND) PT Set at $163.00 by HC Wainwright
www.americanbankingnews.com - November 28 at 11:20 AM
 Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Announce Quarterly Sales of $45.04 Million Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Announce Quarterly Sales of $45.04 Million
www.americanbankingnews.com - November 28 at 6:56 AM
Ligand Pharmaceuticals Incorporated (LGND) Receives Consensus Rating of "Buy" from AnalystsLigand Pharmaceuticals Incorporated (LGND) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 26 at 7:46 AM
Roth Capital Analysts Give Ligand Pharmaceuticals Incorporated (LGND) a $158.00 Price TargetRoth Capital Analysts Give Ligand Pharmaceuticals Incorporated (LGND) a $158.00 Price Target
www.americanbankingnews.com - November 25 at 5:28 PM
Ligand Pharmaceuticals (LGND) Buy Rating Reiterated at HC WainwrightLigand Pharmaceuticals' (LGND) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 22 at 4:26 PM
Ligand Pharmaceuticals Inc. (LGND) Dropped To Over A 2-Month LowLigand Pharmaceuticals Inc. (LGND) Dropped To Over A 2-Month Low
www.rttnews.com - November 22 at 1:54 AM
Ligand Pharmaceuticals Incorporated (LGND) Downgraded by Deutsche Bank AG to SellLigand Pharmaceuticals Incorporated (LGND) Downgraded by Deutsche Bank AG to Sell
www.americanbankingnews.com - November 20 at 8:52 PM
Ligand Pharmaceuticals Incorporated (LGND) PT Set at $159.00 by HC WainwrightLigand Pharmaceuticals Incorporated (LGND) PT Set at $159.00 by HC Wainwright
www.americanbankingnews.com - November 19 at 5:38 PM
Ligand Pharmaceuticals Incorporated (LGND) Stock Rating Reaffirmed by Craig HallumLigand Pharmaceuticals Incorporated (LGND) Stock Rating Reaffirmed by Craig Hallum
www.americanbankingnews.com - November 19 at 10:24 AM
Ligand Pharmaceuticals Incorporated (LGND) Director John W. Kozarich Sells 5,000 SharesLigand Pharmaceuticals Incorporated (LGND) Director John W. Kozarich Sells 5,000 Shares
www.americanbankingnews.com - November 17 at 8:12 PM
Ligand Pharmaceuticals Incorporated (LGND) VP Matthew E. Korenberg Sells 6,559 SharesLigand Pharmaceuticals Incorporated (LGND) VP Matthew E. Korenberg Sells 6,559 Shares
www.americanbankingnews.com - November 17 at 8:12 PM
Ligand Pharmaceuticals Incorporated (LGND) CEO John L. Higgins Sells 5,269 SharesLigand Pharmaceuticals Incorporated (LGND) CEO John L. Higgins Sells 5,269 Shares
www.americanbankingnews.com - November 17 at 8:11 PM
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic DiseaseUltragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
finance.yahoo.com - November 17 at 6:31 PM
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : November 15, 2017Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : November 15, 2017
finance.yahoo.com - November 17 at 1:16 PM
Ligand Pharma (LGND) Offers Highlights from Todays Analyst Day Event - StreetInsider.comLigand Pharma (LGND) Offers Highlights from Today's Analyst Day Event - StreetInsider.com
www.streetinsider.com - November 15 at 4:07 AM
Ligand Provides Highlights from Today’s Analyst Day EventLigand Provides Highlights from Today’s Analyst Day Event
finance.yahoo.com - November 15 at 4:07 AM
Ligand Pharmaceuticals Incorporated (LGND) Issues FY17 Earnings GuidanceLigand Pharmaceuticals Incorporated (LGND) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 14 at 9:18 PM
AstraZeneca Gets Positive CHMP Opinion for Asthma CandidateAstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
finance.yahoo.com - November 13 at 1:13 PM
Arena (ARNA) Completes Enrolment in Etrasimod Phase II StudyArena (ARNA) Completes Enrolment in Etrasimod Phase II Study
finance.yahoo.com - November 13 at 1:13 PM
Ligand Reports Third Quarter 2017 Financial ResultsLigand Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 11 at 4:35 PM
Ligand tops 3Q revenue forecastsLigand tops 3Q revenue forecasts
finance.yahoo.com - November 11 at 4:35 PM

SEC Filings

Ligand Pharmaceuticals (NASDAQ:LGND) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ligand Pharmaceuticals (NASDAQ:LGND) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ligand Pharmaceuticals (NASDAQ LGND) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.